FY2026 Earnings Estimate for Amgen Issued By Leerink Partnrs

Amgen Inc. (NASDAQ:AMGN - Free Report) - Research analysts at Leerink Partnrs lowered their FY2026 earnings per share estimates for Amgen in a research note issued to investors on Wednesday, October 30th. Leerink Partnrs analyst D. Risinger now expects that the medical research company will post earnings per share of $18.56 for the year, down from their previous estimate of $18.66. The consensus estimate for Amgen's current full-year earnings is $19.48 per share. Leerink Partnrs also issued estimates for Amgen's FY2027 earnings at $18.71 EPS.

Several other analysts have also recently commented on AMGN. Dbs Bank raised shares of Amgen to a "strong-buy" rating in a research note on Monday, September 16th. StockNews.com raised Amgen from a "buy" rating to a "strong-buy" rating in a research report on Friday. Barclays increased their target price on Amgen from $300.00 to $315.00 and gave the stock an "equal weight" rating in a research report on Monday, October 7th. Wells Fargo & Company cut Amgen from an "overweight" rating to an "equal weight" rating and lifted their price target for the company from $320.00 to $335.00 in a report on Wednesday, August 7th. Finally, Cantor Fitzgerald reiterated an "overweight" rating and set a $405.00 price objective on shares of Amgen in a report on Tuesday, October 22nd. One analyst has rated the stock with a sell rating, eleven have assigned a hold rating, eleven have assigned a buy rating and two have assigned a strong buy rating to the company's stock. Based on data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average target price of $333.50.

Amgen Trading Down 0.3 %

Shares of NASDAQ AMGN traded down $0.94 during midday trading on Friday, reaching $319.22. 1,826,745 shares of the stock were exchanged, compared to its average volume of 2,418,089. The stock has a 50 day moving average price of $324.47 and a 200-day moving average price of $315.19. The company has a current ratio of 1.26, a quick ratio of 0.89 and a debt-to-equity ratio of 9.64. The company has a market capitalization of $171.53 billion, a P/E ratio of 40.87, a P/E/G ratio of 2.84 and a beta of 0.61. Amgen has a 52-week low of $260.52 and a 52-week high of $346.85.

Amgen (NASDAQ:AMGN - Get Free Report) last posted its quarterly earnings data on Wednesday, October 30th. The medical research company reported $5.58 EPS for the quarter, topping analysts' consensus estimates of $5.11 by $0.47. The firm had revenue of $8.50 billion during the quarter, compared to analysts' expectations of $8.50 billion. Amgen had a return on equity of 181.58% and a net margin of 13.00%. The firm's quarterly revenue was up 23.2% compared to the same quarter last year. During the same quarter last year, the business posted $4.96 EPS.

Institutional Trading of Amgen

Several large investors have recently bought and sold shares of AMGN. Vanguard Group Inc. increased its stake in Amgen by 6.2% during the 1st quarter. Vanguard Group Inc. now owns 52,088,210 shares of the medical research company's stock worth $14,809,720,000 after buying an additional 3,045,657 shares during the period. Capital International Investors increased its position in shares of Amgen by 547.8% during the first quarter. Capital International Investors now owns 7,005,269 shares of the medical research company's stock worth $1,991,738,000 after acquiring an additional 5,923,915 shares during the last quarter. Pathway Financial Advisers LLC lifted its stake in shares of Amgen by 33,125.4% in the third quarter. Pathway Financial Advisers LLC now owns 4,460,181 shares of the medical research company's stock worth $1,437,115,000 after acquiring an additional 4,446,757 shares in the last quarter. Dimensional Fund Advisors LP lifted its stake in shares of Amgen by 6.4% in the second quarter. Dimensional Fund Advisors LP now owns 2,701,631 shares of the medical research company's stock worth $844,137,000 after acquiring an additional 162,223 shares in the last quarter. Finally, International Assets Investment Management LLC boosted its holdings in Amgen by 6,812.4% in the third quarter. International Assets Investment Management LLC now owns 2,523,387 shares of the medical research company's stock valued at $8,130,610,000 after purchasing an additional 2,486,882 shares during the last quarter. Institutional investors and hedge funds own 76.50% of the company's stock.

Amgen Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Monday, December 9th. Shareholders of record on Monday, November 18th will be issued a $2.25 dividend. This represents a $9.00 dividend on an annualized basis and a yield of 2.82%. The ex-dividend date of this dividend is Monday, November 18th. Amgen's dividend payout ratio is presently 115.24%.

Amgen Company Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.